Xolair market seen expanding through 2030 as asthma cases rise

Nov. 20, 2026
Xolair market seen expanding through 2030 as asthma cases rise
By AI, Created 00:30 UTC, Nov 20, 2026, AGP -

The Business Research Company says the global Xolair market is set to grow through 2030, driven by rising asthma and allergic disease rates, wider biologic use and greater demand for personalized treatment. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - The Xolair market is tied to the broader rise in asthma and allergy treatment demand worldwide. - Growth in biologic therapies is pushing more attention toward targeted medicines for chronic allergic disease. - The forecast points to stronger demand for specialty immunology drugs as healthcare systems expand access to advanced treatments.

What happened: - The Business Research Company published a market forecast for Xolair through 2030. - The report covers Xolair, also known as omalizumab, a monoclonal antibody used for moderate to severe asthma, chronic idiopathic urticaria and nasal polyps. - The company said the market grew steadily in the historical period and is expected to keep expanding during the forecast period. - The release was published Nov. 20, 2026.

The details: - Xolair works by targeting immunoglobulin E, or IgE, to reduce allergic inflammation and improve symptom control. - The treatment is typically used when asthma or related conditions remain inadequately controlled with conventional therapy. - Historical growth was linked to higher asthma and allergy rates, more biologic approvals, higher diagnosis rates for chronic urticaria, more specialty allergy clinics and greater physician familiarity with monoclonal antibodies. - Future growth is expected to come from demand for personalized allergy treatment, broader biologic use in inflammatory diseases, more investment in immunology research, wider use of long-acting injectables and better access to specialty biologic drugs. - Key market trends include greater uptake of targeted monoclonal antibody therapies, rising biologic use for chronic allergic disease, longer-term disease management strategies, precision immunology and patient-centric biologic care. - North America held the largest share of the Xolair market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - Western Europe, Eastern Europe, South America, the Middle East and Africa were also included in the regional analysis. - The report’s new 2026 additions include market attractiveness scoring, TAM analysis, a company scoring matrix, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables. - The company offered a free sample report and the full report through links in the release: Download a free sample and View the full report. - The release also listed contact details for Saumya Sahay and The Business Research Company.

Between the lines: - The forecast reflects a broader industry shift toward biologics that treat the underlying drivers of allergic disease instead of only managing symptoms. - The regional split suggests mature demand in North America and faster expansion in markets where access and awareness are still improving. - The cited U.S. asthma data from the National Center for Health Statistics shows prevalence among adults rose from 3.7% in 2022 to 3.8% in 2023, reinforcing the market case for additional treatment options.

What's next: - The market outlook will depend on how quickly biologics gain broader adoption in allergy and asthma care. - Continued investment in immunology research and specialty access will likely shape the next phase of growth. - Regional momentum in Asia-Pacific could narrow the gap with North America if healthcare access and biologic uptake continue to rise.

The bottom line: - Xolair remains positioned as a key biologic in a market where asthma, allergies and precision immunology are all moving in the same direction.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Healthy Living Europe

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Healthy Living Europe

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.